PHPeter M. Haggie

Peter M. Haggie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter M. Haggie has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SLC26A6-selective inhibitor identified in a small-molecule screen blocks fluid absorption in small intestine

    by Onur Cil, Peter M. Haggie, Joseph-Anthony Tapia Tan, Amber A. Rivera, Alan S. Verkman

    SLC26A6 (also known as putative anion transporter 1 [PAT1]) is a Cl – /HCO 3 – exchanger expressed at the luminal membrane of enterocytes where it facilitates intestinal Cl – and fluid absorption. Here, high-throughput screening of 50,000 synthetic small molecules in cells expressing PAT1 and a halide-sensing fluorescent protein identified several classes of inhibitors. The most potent compound, the pyrazolo-pyrido-pyrimidinone PAT1 inh -B01, fully inhibited PAT1-mediated anion exchange (IC 50 ~350 nM), without inhibition of the related intestinal transporter SLC26A3 (also known as DRA). In closed midjejunal loops in mice, PAT1 inh -B01 inhibited fluid absorption by 50%, which increased to >90% when coadministered with DRA inhibitor DRA inh -A270. In ileal loops, PAT1 inh -B01 blocked fluid absorption by >80%, whereas DRA inh -A270 was without effect. In colonic loops, PAT1 inh -B01 was without effect, whereas DRA inh -A270 completely blocked fluid absorption. In a loperamide constipation model, coadministration of PAT1 inh -B01 with DRA inh -A270 increased stool output compared with DRA inh -A270 alone. These results provide functional evidence for complementary and region-specific roles of PAT1 and DRA in intestinal fluid absorption, with PAT1 as the predominant anion exchanger in mouse ileum. We believe that PAT1 inh -B01 is a novel tool to study intestinal ion and fluid transport and perhaps a drug candidate for small intestinal hyposecretory disorders such as cystic fibrosis–related meconium ileus and distal intestinal obstruction syndrome.


  • 1-BENZYLSPIRO[PIPERIDINE-4,1′-PYRIDO[3,4-b]indole] ‘co-potentiators’ for minimal function CFTR mutants

    by Jung-Ho Son, Puay-Wah Phuan, Jie S. Zhu, Soren Lipman, Amy Cheung, Ka Yi Tsui, Dean J. Tantillo, Alan S. Verkman, Peter M. Haggie, Mark J. Kurth


  • CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation

    by Puay-Wah Phuan, Peter M. Haggie, Joseph A. Tan, Amber A. Rivera, Walter E. Finkbeiner, Dennis W. Nielson, Merlin M. Thomas, Ibrahim A. Janahi, Alan S. Verkman


  • Open Access

    Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation

    by Guadalupe Ortiz-Muñoz, Michelle A. Yu, Emma Lefrançais, Beñat Mallavia, Colin Valet, Jennifer J. Tian, Serena Ranucci, Kristin M. Wang, Zhe Liu, Nicholas Kwaan, et al.

    Cystic fibrosis (CF) lung disease is characterized by an inflammatory response that can lead to terminal respiratory failure. The cystic fibrosis transmembrane conductance regulator (CFTR) is mutated in CF, and we hypothesized that dysfunctional CFTR in platelets, which are key participants in immune responses, is a central determinant of CF inflammation. We found that deletion of CFTR in platelets produced exaggerated acute lung inflammation and platelet activation after intratracheal LPS or Pseudomonas aeruginosa challenge. CFTR loss of function in mouse or human platelets resulted in agonist-induced hyperactivation and increased calcium entry into platelets. Inhibition of the transient receptor potential cation channel 6 (TRPC6) reduced platelet activation and calcium flux, and reduced lung injury in CF mice after intratracheal LPS or Pseudomonas aeruginosa challenge. CF subjects receiving CFTR modulator therapy showed partial restoration of CFTR function in platelets, which may be a convenient approach to monitoring biological responses to CFTR modulators. We conclude that CFTR dysfunction in platelets produces aberrant TRPC6-dependent platelet activation, which is a major driver of CF lung inflammation and impaired bacterial clearance. Platelets and TRPC6 are what we believe to be novel therapeutic targets in the treatment of CF lung disease.


  • Open Access

    SLC26A3 inhibitor identified in small molecule screen blocks colonic fluid absorption and reduces constipation

    by Peter M. Haggie, Onur Cil, Sujin Lee, Joseph-Anthony Tan, Amber A. Rivera, Puay-Wah Phuan, Alan S. Verkman

    SLC26A3 (downregulated in adenoma; DRA) is a Cl – /anion exchanger expressed in the luminal membrane of intestinal epithelial cells, where it facilitates electroneutral NaCl absorption. SLC26A3 loss of function in humans or mice causes chloride-losing diarrhea. Here, we identified slc26a3 inhibitors in a screen of 50,000 synthetic small molecules done in Fischer rat thyroid (FRT) cells coexpressing slc26a3 and a genetically encoded halide sensor. Structure-activity relationship studies were done on the most potent inhibitor classes identified in the screen: 4,8-dimethylcoumarins and acetamide-thioimidazoles. The dimethylcoumarin DRA inh -A250 fully and reversibly inhibited slc26a3-mediated Cl – exchange with HCO 3 – , I – , and thiocyanate (SCN – ), with an IC 50 of ~0.2 μM. DRA inh -A250 did not inhibit the homologous anion exchangers slc26a4 (pendrin) or slc26a6 (PAT-1), nor did it alter activity of other related proteins or intestinal ion channels. In mice, intraluminal DRA inh -A250 blocked fluid absorption in closed colonic loops but not in jejunal loops, while the NHE3 (SLC9A3) inhibitor tenapanor blocked absorption only in the jejunum. Oral DRA inh -A250 and tenapanor comparably reduced signs of constipation in loperamide-treated mice, with additive effects found on coadministration. DRA inh -A250 was also effective in loperamide-treated cystic fibrosis mice. These studies support a major role of slc26a3 in colonic fluid absorption and suggest the therapeutic utility of SLC26A3 inhibition in constipation.


  • Open Access

    Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product

    by Peter M. Haggie, Puay-Wah Phuan, Joseph-Anthony Tan, Haijin Xu, Radu G. Avramescu, Doranda Perdomo, Lorna Zlock, Dennis W. Nielson, Walter E. Finkbeiner, Gergely L. Lukacs, et al.


  • Open Access

    X-Box Binding Protein 1 (XBP1s) Is a Critical Determinant of Pseudomonas aeruginosa Homoserine Lactone-Mediated Apoptosis

    by Cathleen D. Valentine, Marc O. Anderson, Feroz R. Papa, Peter M. Haggie

    Pseudomonas aeruginosa infections are associated with high mortality rates and occur in diverse conditions including pneumonias, cystic fibrosis and neutropenia. Quorum sensing, mediated by small molecules including N-(3-oxo-dodecanoyl) homoserine lactone (C12), regulates P. aeruginosa growth and virulence. In addition, host cell recognition of C12 initiates multiple signalling responses including cell death. To gain insight into mechanisms of C12-mediated cytotoxicity, we studied the role of endoplasmic reticulum stress in host cell responses to C12. Dramatic protection against C12-mediated cell death was observed in cells that do not produce the X-box binding protein 1 transcription factor (XBP1s). The leucine zipper and transcriptional activation motifs of XBP1s were sufficient to restore C12-induced caspase activation in XBP1s-deficient cells, although this polypeptide was not transcriptionally active. The XBP1s polypeptide also regulated caspase activation in cells stimulated with N-(3-oxo-tetradecanoyl) homoserine lactone (C14), produced by Yersinia enterolitica and Burkholderia pseudomallei, and enhanced homoserine lactone-mediated caspase activation in the presence of endogenous XBP1s. In C12-tolerant cells, responses to C12 including phosphorylation of p38 MAPK and eukaryotic initiation factor 2α were conserved, suggesting that C12 cytotoxicity is not heavily dependent on these pathways. In summary, this study reveals a novel and unconventional role for XBP1s in regulating host cell cytotoxic responses to bacterial acyl homoserine lactones. Chronic and acute infections associated with P. aeruginosa constitute a major healthcare burden. Antimicrobial approaches are currently used against P. aeruginosa; however, infections are typically refractory to treatment and drug resistant strains have been isolated. As such, there is urgent need to understand mechanisms of P. aeruginosa virulence and for new strategies to fight infections. The P. aeruginosa-derived quorum-sensing molecule C12 is recognized by host cells and initiates stress responses including cytotoxicity. In this study, the X-box binding protein 1 transcription factor (XBP1s) was identified as a host factor critical for apoptotic responses initiated by C12 and other similar quorum sensing molecules. Additional C12-initiated host responses, including phosphorylation of p38 MAPK and eIF2α were found to be of lesser importance for C12-initiated cytotoxicity. These studies have broad implications for our understanding of bacterial virulence mechanisms and for development of potential new strategies to combat infections.


  • Open Access

    Small molecule screen yields inhibitors of pseudomonas homoserine lactone-induced host responses

    by Cathleen D. Valentine, Hua Zhang, Puay-Wah Phuan, Juliane Nguyen, A. S. Verkman, Peter M. Haggie

    Pseudomonas aeruginosa infections are commonly associated with cystic fibrosis, pneumonias, neutropenia and burns. The P. aeruginosa quorum sensing molecule N‐(3‐oxo‐dodecanoyl) homoserine lactone (C12) cause multiple deleterious host responses, including repression of NF‐κB transcriptional activity and apoptosis. Inhibition of C12‐mediated host responses is predicted to reduce P. aeruginosa virulence. We report here a novel, host‐targeted approach for potential adjunctive anti‐Pseudomonal therapy based on inhibition of C12‐mediated host responses. A high‐throughput screen was developed to identify C12 inhibitors that restore NF‐κB activity in C12‐treated, lipopolysaccharide (LPS)‐stimulated cells. Triazolo[4,3‐a]quinolines with nanomolar potency were identified as C12‐inhibitors that restore NF‐κB‐dependent luciferase expression in LPS‐ and TNF‐stimulated cell lines. In primary macrophages and fibroblasts, triazolo[4,3‐a]quinolines inhibited C12 action to restore cytokine secretion in LPS‐stimulated cells. Serendipitously, in the absence of an inflammatory stimulus, triazolo[4,3‐a]quinolines prevented C12‐mediated responses, including cytotoxicity, elevation of cytoplasmic calcium, and p38 MAPK phosphorylation. In vivo efficacy was demonstrated in a murine model of dermal inflammation involving intradermalC12 administration. The discovery of triazolo[4,3‐a]quinolines provides a pharmacological tool to investigate C12‐mediated host responses, and a potential host‐targeted anti‐Pseudomonal therapy.


  • Open Access

    Reduced PDZ Interactions of Rescued ΔF508CFTR Increases Its Cell Surface Mobility

    by Cathleen D. Valentine, Gergely L. Lukacs, Alan S. Verkman, Peter M. Haggie


  • Open Access

    Protein Trafficking Rates Assessed by Quantum Dot Quenching with Bromocresol Green

    by Cathleen D. Valentine, A.S. Verkman, Peter M. Haggie

    Quantum dots are bright, photostable fluorophores used extensively to investigate biological processes. In this study, we report that bromocresol green (BCG) at low micromolar concentrations rapidly, efficiently and reversibly quenches the fluorescence of commercial quantum dots having a wide range of functionalities. The broad utility of BCG quenching of quantum dots in cell biology is showed in quantitative assays of trafficking of the β2‐adrenergic receptor (β2AR) and the cystic fibrosis transmembrane conductance regulator (CFTR).